Takeda Says Orexigen's Ch. 11 Plan Exposes It To $6M Claim
Takeda Pharmaceutical Co. objected Monday to the proposed Chapter 11 liquidation plan of Orexigen Therapeutics Inc., saying it didn't have the chance to opt out of third-party releases that would hamper...To view the full article, register now.
Already a subscriber? Click here to view full article